Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Weber

Showing results (1-10 of 104) with videos related to

Pageof 11
Sort By:
ESMO Open|April 12, 2018
Recent advances in adjuvant therapy for patients with melanomaJeffrey Weber
The Oncologist|November 15, 2008
Introduction. Immune-modulating antibodiesJeffrey Weber
Cancer Immunology, Immunotherapy : CII|February 10, 2009
Ipilimumab: controversies in its development, utility and autoimmune adverse eventsJeffrey Weber
Current Opinion in Oncology|December 31, 2010
Immunotherapy for melanomaJeffrey Weber
The Oncologist|August 4, 2007
Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse eventsJeffrey Weber
The Oncologist|November 15, 2008
Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010)Jeffrey Weber
Cancer Investigation|March 21, 2002
Peptide vaccines for cancerJeffrey Weber
Seminars in Oncology|November 16, 2010
Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockadeJeffrey Weber
Seminars in Oncology|May 13, 2015
Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinationsKathryn Baksh, Jeffrey Weber
Cancer Journal (Sudbury, Mass.)|March 25, 2024
Melanoma-Modern Treatment for Metastatic MelanomaMaya Dimitrova, Jeffrey Weber
Pageof 11

Showing results (1-10 of 104) with videos related to

Sort By:
Pageof 11
ESMO Open|April 12, 2018
Recent advances in adjuvant therapy for patients with melanomaJeffrey Weber
The Oncologist|November 15, 2008
Introduction. Immune-modulating antibodiesJeffrey Weber
Cancer Immunology, Immunotherapy : CII|February 10, 2009
Ipilimumab: controversies in its development, utility and autoimmune adverse eventsJeffrey Weber
Current Opinion in Oncology|December 31, 2010
Immunotherapy for melanomaJeffrey Weber
The Oncologist|August 4, 2007
Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse eventsJeffrey Weber
The Oncologist|November 15, 2008
Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010)Jeffrey Weber
Cancer Investigation|March 21, 2002
Peptide vaccines for cancerJeffrey Weber
Seminars in Oncology|November 16, 2010
Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockadeJeffrey Weber
Seminars in Oncology|May 13, 2015
Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinationsKathryn Baksh, Jeffrey Weber
Cancer Journal (Sudbury, Mass.)|March 25, 2024
Melanoma-Modern Treatment for Metastatic MelanomaMaya Dimitrova, Jeffrey Weber
Pageof 11